Comparison · NCT02269475-a1ee5b1b
MEDI3250 vs Placebo: the Incidence of Laboratory-confirmed Influenza Infection (Matched Strain)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. MEDI3250 vs Placebo: the Incidence of Laboratory-confirmed Influenza Infection (Matched Strain). Trial comparisons, record NCT02269475-a1ee5b1b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02269475-a1ee5b1b
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.0045 | wilson | |
| Risk in group 2 | 0.00233 | 0.000411 | 0.0131 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00233 | -0.0131 | 0.00257 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one fewer participant with the outcome on MEDI3250 than on Placebo | 430 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | MEDI3250 | MEDI3250, 0.2mL as nasal spray | 0 | 849 | OG000 |
| Group 2 | Placebo | Placebo, 0.2mL as nasal spray | 1 | 430 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- the Incidence of Laboratory-confirmed Influenza Infection (Matched Strain)
- Description
- The vaccine efficacy of MEDI3250 compared to placebo against the incidence of laboratory-confirmed influenza infection (matched strain)
- Time frame
- through the end of the influenza surveillance period, up to end Apr (6 months)
- Population
- Per Protocol Population
Source ClinicalTrials.gov
Trial
- Title
- A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 Years
- NCT number
- NCT02269475
- Phases
- PHASE3
- Conditions
- Healthy Japanese Children Age 7 Years Through 18 Years
- Interventions
- MEDI3250, Placebo
- Lead sponsor
- AstraZeneca
- Results first posted
- 2015-12-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02269475?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02269475-a1ee5b1b